Top

Published in:

01-05-2020 | Original Research

New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis

Authors: Yuejiao Xin, Yang Liu, Dandan Liu, Jie Li, Chenying Zhang, Yixiang Wang, Shuguo Zheng

Published in: Calcified Tissue International | Issue 5/2020

Abstract

Cleidocranial dysplasia is an autosomal dominant skeletal disorder resulting from RUNX2 mutations. The influence of RUNX2 mutations on osteoclastogenesis and bone resorption have not been reported. To investigate the role of RUNX2 in osteoclast, RUNX2 expression in macrophages (RAW 264.7 cells) was detected. Stable RAW 264.7 cell lines expressing wild-type RUNX2 or mutated RUNX2 (c.514delT, p.172 fs) were established, and their functions in osteoclasts were investigated. Wild-type RUNX2 promoted osteoclast differentiation, formation of F-actin ring, and bone resorption, while mutant RUNX2 attenuated the positive differentiation effect. Wild-type RUNX2 increased the expression and activity of mTORC2. Subsequently, mTORC2 specifically promoted phosphorylation of AKT at the serine 473 residue. Activated AKT improved the nuclear translocation of NFATc1 and increased the expression of downstream genes, including CTSK. Inhibition of AKT phosphorylation abrogated the osteoclast formation of wild-type macrophages, whereas constitutively activated AKT rescued the osteoclast formation of mutant macrophages. The present study suggested that RUNX2 promotes osteoclastogenesis and bone resorption through the AKT/NFATc1/CTSK axis. Mutant RUNX2 lost the function of regulating osteoclast differentiation and bone remodeling, resulting in the defective formation of the tooth eruption pathway and impaction of permanent teeth in cleidocranial dysplasia. This study, for the first time, verifies the effect of RUNX2 on osteoclast differentiation and bone resorption and provides new insight for the explanation of cleidocranial dysplasia.

Ott CE, Leschik G, Trotier F, Brueton L, Brunner HG, Brussel W, Guillen-Navarro E, Haase C, Kohlhase J, Kotzot D, Lane A, Lee-Kirsch MA, Morlot S, Simon ME, Steichen-Gersdorf E, Tegay DH, Peters H, Mundlos S, Klopocki E (2010) Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasia. Hum Mutat 31(8):E1587–1593. https://doi.org/10.1002/humu.21298 CrossRefPubMed

Cooper SC, Flaitz CM, Johnston DA, Lee B, Hecht JT (2001) A natural history of cleidocranial dysplasia. Am J Med Genet 104(1):1–6CrossRef

Zhang CY, Zheng SG, Wang YX, Zhu JX, Zhu X, Zhao YM, Ge LH (2009) Novel RUNX2 mutations in Chinese individuals with cleidocranial dysplasia. J Dental Res 88(9):861–866. https://doi.org/10.1177/0022034509342083 CrossRef

Jaruga A, Hordyjewska E, Kandzierski G, Tylzanowski P (2016) Cleidocranial dysplasia and RUNX2-clinical phenotype-genotype correlation. Clin Genet 90(5):393–402. https://doi.org/10.1111/cge.12812 CrossRefPubMed

Wise GE (2009) Cellular and molecular basis of tooth eruption. Orthod Cranio Res 12(2):67–73. https://doi.org/10.1111/j.1601-6343.2009.01439.x CrossRef

Wise GE, He H, Gutierrez DL, Ring S, Yao S (2011) Requirement of alveolar bone formation for eruption of rat molars. Eur J Oral Sci 119(5):333–338. https://doi.org/10.1111/j.1600-0722.2011.00854.x CrossRefPubMedPubMedCentral

Wise GE, Yao S (2006) Regional differences of expression of bone morphogenetic protein-2 and RANKL in the rat dental follicle. Eur J Oral Sci 114(6):512–516. https://doi.org/10.1111/j.1600-0722.2006.00406.x CrossRefPubMed

Castaneda B, Simon Y, Jacques J, Hess E, Choi YW, Blin-Wakkach C, Mueller C, Berdal A, Lezot F (2011) Bone resorption control of tooth eruption and root morphogenesis: involvement of the receptor activator of NF-kappaB (RANK). J Cell Physiol 226(1):74–85. https://doi.org/10.1002/jcp.22305 CrossRefPubMed

Wise GE, Yao S, Henk WG (2007) Bone formation as a potential motive force of tooth eruption in the rat molar. Clin Anat 20(6):632–639. https://doi.org/10.1002/ca.20495 CrossRefPubMed

10.

Takarada T, Hinoi E, Nakazato R, Ochi H, Xu C, Tsuchikane A, Takeda S, Karsenty G, Abe T, Kiyonari H, Yoneda Y (2013) An analysis of skeletal development in osteoblast-specific and chondrocyte-specific runt-related transcription factor-2 (Runx2) knockout mice. J Bone Miner Res 28(10):2064–2069. https://doi.org/10.1002/jbmr.1945 CrossRefPubMed

11.

Chen P, Wei D, Xie B, Ni J, Xuan D, Zhang J (2014) Effect and possible mechanism of network between microRNAs and RUNX2 gene on human dental follicle cells. J Cell Biochem 115(2):340–348. https://doi.org/10.1002/jcb.24668 CrossRefPubMed

12.

Yan WJ, Zhang CY, Yang X, Liu ZN, Wang XZ, Sun XY, Wang YX, Zheng SG (2015) Abnormal differentiation of dental pulp cells in cleidocranial dysplasia. J Dental Res 94(4):577–583. https://doi.org/10.1177/0022034514566655 CrossRef

13.

Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87(18):7260–7264. https://doi.org/10.1073/pnas.87.18.7260 CrossRefPubMed

14.

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165–176CrossRef

15.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597–3602. https://doi.org/10.1073/pnas.95.7.3597 CrossRefPubMed

16.

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20(3):345–357. https://doi.org/10.1210/edrv.20.3.0367 CrossRefPubMed

17.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T (2003) Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. J Biol Chem 278(26):23971–23977. https://doi.org/10.1074/jbc.M302457200 CrossRefPubMed

18.

Martin A, Xiong J, Koromila T, Ji JS, Chang S, Song YS, Miller JL, Han CY, Kostenuik P, Krum SA, Chimge NO, Gabet Y, Frenkel B (2015) Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone 75:96–104. https://doi.org/10.1016/j.bone.2015.02.007 CrossRefPubMedPubMedCentral

19.

Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, Chen Y (2011) Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 31(6):1387–1396. https://doi.org/10.1161/atvbaha.110.222547 CrossRefPubMedPubMedCentral

20.

Zhang C, Zheng S, Wang Y, Zhao Y, Zhu J, Ge L (2010) Mutational analysis of RUNX2 gene in Chinese patients with cleidocranial dysplasia. Mutagenesis 25(6):589–594. https://doi.org/10.1093/mutage/geq044 CrossRefPubMed

21.

Liu Y, Sun X, Zhang X, Wang X, Zhang C, Zheng S (2019) RUNX2 mutation impairs osteogenic differentiation of dental follicle cells. Arch Oral Biol 97:156–164. https://doi.org/10.1016/j.archoralbio.2018.10.029 CrossRefPubMed

22.

Dincsoy Bir F, Dinckan N, Guven Y, Bas F, Altunoglu U, Kuvvetli SS, Poyrazoglu S, Toksoy G, Kayserili H, Uyguner ZO (2017) Cleidocranial dysplasia: clinical, endocrinologic and molecular findings in 15 patients from 11 families. Eur J Med Genet 60(3):163–168. https://doi.org/10.1016/j.ejmg.2016.12.007 CrossRefPubMed

23.

Mundlos S (1999) Cleidocranial dysplasia: clinical and molecular genetics. J Med Genet 36(3):177–182PubMedPubMedCentral

24.

Bergwitz C, Prochnau A, Mayr B, Kramer FJ, Rittierodt M, Berten HL, Hausamen JE, Brabant G (2001) Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia. J Inherit Metab Dis 24(6):648–656. https://doi.org/10.1023/a:1012758925617 CrossRefPubMed

25.

Yoshida T, Kanegane H, Osato M, Yanagida M, Miyawaki T, Ito Y, Shigesada K (2002) Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am J Hum Genet 71(4):724–738. https://doi.org/10.1086/342717 CrossRefPubMedPubMedCentral

26.

Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N (2009) Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 583(14):2435–2440. https://doi.org/10.1016/j.febslet.2009.06.047 CrossRefPubMed

27.

Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40(2):251–264. https://doi.org/10.1016/j.bone.2006.09.023 CrossRefPubMed

28.

Lu SY, Li M, Lin YL (2014) Mitf regulates osteoclastogenesis by modulating NFATc1 activity. Exp Cell Res 328(1):32–43. https://doi.org/10.1016/j.yexcr.2014.08.018 CrossRefPubMedPubMedCentral

29.

Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y (2004) Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279 (44):45969–45979. https://doi.org/10.1074/jbc.M408795200 CrossRefPubMed

30.

Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF (2004) Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279(25):26475–26480. https://doi.org/10.1074/jbc.M313973200 CrossRefPubMed

31.

Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, Kim N (2012) Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. J Immunol 188(1):163–169. https://doi.org/10.4049/jimmunol.1101254 CrossRefPubMed

32.

Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12(4):487–502. https://doi.org/10.1016/j.devcel.2007.03.020 CrossRefPubMed

33.

Wu M, Chen W, Lu Y, Zhu G, Hao L, Li YP (2017) Galpha13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3beta-NFATc1 signalling pathway. Nat Commun 8:13700. https://doi.org/10.1038/ncomms13700 CrossRefPubMedPubMedCentral

34.

Jang HD, Shin JH, Park DR, Hong JH, Yoon K, Ko R, Ko CY, Kim HS, Jeong D, Kim N, Lee SY (2011) Inactivation of glycogen synthase kinase-3beta is required for osteoclast differentiation. J Biol Chem 286(45):39043–39050. https://doi.org/10.1074/jbc.M111.256768 CrossRefPubMedPubMedCentral

35.

Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69(5):1821–1827. https://doi.org/10.1158/0008-5472.can-08-3014 CrossRefPubMedPubMedCentral

36.

Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67(24):11712–11720. https://doi.org/10.1158/0008-5472.can-07-2223 CrossRefPubMed

37.

Huang S, Yang ZJ, Yu C, Sinicrope FA (2011) Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem 286(46):40002–40012. https://doi.org/10.1074/jbc.M111.297432 CrossRefPubMedPubMedCentral

38.

Tandon M, Chen Z, Pratap J (2014) Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res 16(1):R16. https://doi.org/10.1186/bcr3611 CrossRefPubMedPubMedCentral

39.

Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Investig 123(2):666–681. https://doi.org/10.1172/jci64840 CrossRefPubMed

40.

Chen W, Yang S, Abe Y, Li M, Wang Y, Shao J, Li E, Li YP (2007) Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 16(4):410–423. https://doi.org/10.1093/hmg/ddl474 CrossRefPubMedPubMedCentral

41.

Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95(23):13453–13458. https://doi.org/10.1073/pnas.95.23.13453 CrossRefPubMed

42.

Panwar P, Soe K, Guido RV, Bueno RV, Delaisse JM, Bromme D (2016) A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K. Br J Pharmacol 173(2):396–410. https://doi.org/10.1111/bph.13383 CrossRefPubMed

43.

Prates TP, Taira TM, Holanda MC, Bignardi LA, Salvador SL, Zamboni DS, Cunha FQ, Fukada SY (2014) NOD2 contributes to Porphyromonas gingivalis-induced bone resorption. J Dental Res 93(11):1155–1162. https://doi.org/10.1177/0022034514551770 CrossRef

44.

Sharmin F, McDermott C, Lieberman J, Sanjay A, Khan Y (2017) Dual growth factor delivery from biofunctionalized allografts: Sequential VEGF and BMP-2 release to stimulate allograft remodeling. J Orthop Res 35(5):1086–1095. https://doi.org/10.1002/jor.23287 CrossRefPubMed

45.

Faienza MF, Ventura A, Piacente L, Ciccarelli M, Gigante M, Gesualdo L, Colucci S, Cavallo L, Grano M, Brunetti G (2014) Osteoclastogenic potential of peripheral blood mononuclear cells in cleidocranial dysplasia. Int J Med Sci 11(4):356–364. https://doi.org/10.7150/ijms.7793 CrossRefPubMedPubMedCentral

46.

Yoda S, Suda N, Kitahara Y, Komori T, Ohyama K (2004) Delayed tooth eruption and suppressed osteoclast number in the eruption pathway of heterozygous Runx2/Cbfa1 knockout mice. Arch Oral Biol 49(6):435–442. https://doi.org/10.1016/j.archoralbio.2004.01.010 CrossRefPubMed

47.

Collin-Osdoby P, Osdoby P (2012) RANKL-mediated osteoclast formation from murine RAW 264.7 cells. Methods Mol Biol 816:187–202. https://doi.org/10.1007/978-1-61779-415-5_13 CrossRefPubMed

48.

Laha D, Deb M, Das H (2019) KLF2 (kruppel-like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy. Autophagy 15(12):2063–2075. https://doi.org/10.1080/15548627.2019.1596491 CrossRefPubMed

49.

Hao S, Meng J, Zhang Y, Liu J, Nie X, Wu F, Yang Y, Wang C, Gu N, Xu H (2017) Macrophage phenotypic mechanomodulation of enhancing bone regeneration by superparamagnetic scaffold upon magnetization. Biomaterials 140:16–25. https://doi.org/10.1016/j.biomaterials.2017.06.013 CrossRefPubMed

50.

Yamamoto A, Miyazaki T, Kadono Y, Takayanagi H, Miura T, Nishina H, Katada T, Wakabayashi K, Oda H, Nakamura K, Tanaka S (2002) Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res 17(4):612–621. https://doi.org/10.1359/jbmr.2002.17.4.612 CrossRefPubMed

Title: New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis
Authors: Yuejiao Xin
Yang Liu
Dandan Liu
Jie Li
Chenying Zhang
Yixiang Wang
Shuguo Zheng
Publication date: 01-05-2020
Publisher: Springer US
Published in: Calcified Tissue International / Issue 5/2020
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-020-00666-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

The Latest Evidence from Vitamin D Intervention Trials for Non-skeletal Outcomes

Exosomes Secreted by Young Mesenchymal Stem Cells Promote New Bone Formation During Distraction Osteogenesis in Older Rats

Impaired Bone Microarchitecture in Patients with Hereditary Hemochromatosis and Skeletal Complications

Bone Growth is Influenced by Fructose in Adolescent Male Mice Lacking Ketohexokinase (KHK)

Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study

BMP2 Modified by the m6A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage